Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 850.0
(0.7%)
INR 850.0
(0.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 26.78 Billion INR | -19.62% |
| 2022 | 34.76 Billion INR | -0.91% |
| 2021 | 35.08 Billion INR | -6.56% |
| 2020 | 37.54 Billion INR | 18.16% |
| 2019 | 31.77 Billion INR | 21.61% |
| 2018 | 26.13 Billion INR | 32.46% |
| 2017 | 19.72 Billion INR | -1.91% |
| 2016 | 20.11 Billion INR | -4.15% |
| 2015 | 20.98 Billion INR | 67.64% |
| 2014 | 12.51 Billion INR | 17.98% |
| 2013 | 10.6 Billion INR | 36.53% |
| 2012 | 7.77 Billion INR | 13.43% |
| 2011 | 6.85 Billion INR | 12.01% |
| 2010 | 6.11 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 7.18 Billion INR | 7.89% |
| 2023 Q2 | 11.33 Billion INR | 5.67% |
| 2023 FY | 27.94 Billion INR | -19.62% |
| 2023 Q1 | 10.72 Billion INR | 111.66% |
| 2023 Q3 | 11.69 Billion INR | 3.2% |
| 2023 Q4 | 6.66 Billion INR | -43.04% |
| 2022 Q2 | 10.31 Billion INR | 16.76% |
| 2022 FY | 34.76 Billion INR | -0.91% |
| 2022 Q3 | 10.54 Billion INR | 2.13% |
| 2022 Q4 | 5.06 Billion INR | -51.92% |
| 2022 Q1 | 8.83 Billion INR | 30.14% |
| 2021 FY | 35.08 Billion INR | -6.56% |
| 2021 Q2 | 9.59 Billion INR | 1.96% |
| 2021 Q1 | 9.4 Billion INR | 60.87% |
| 2021 Q3 | 9.29 Billion INR | -3.17% |
| 2021 Q4 | 6.79 Billion INR | -26.89% |
| 2020 FY | 37.54 Billion INR | 18.16% |
| 2020 Q4 | 5.84 Billion INR | -42.73% |
| 2020 Q3 | 10.21 Billion INR | -10.81% |
| 2020 Q2 | 11.45 Billion INR | 14.11% |
| 2020 Q1 | 10.03 Billion INR | 81.0% |
| 2019 Q1 | 7.44 Billion INR | 95.18% |
| 2019 FY | 31.77 Billion INR | 21.61% |
| 2019 Q4 | 5.54 Billion INR | -39.12% |
| 2019 Q2 | 9.68 Billion INR | 30.05% |
| 2019 Q3 | 9.1 Billion INR | -5.95% |
| 2018 Q4 | 3.81 Billion INR | -50.44% |
| 2018 Q1 | 6.07 Billion INR | 2.98% |
| 2018 Q2 | 8.55 Billion INR | 40.84% |
| 2018 Q3 | 7.69 Billion INR | -9.98% |
| 2018 FY | 26.13 Billion INR | 32.46% |
| 2017 Q2 | 5.75 Billion INR | 23.55% |
| 2017 FY | 19.72 Billion INR | -1.91% |
| 2017 Q4 | 5.89 Billion INR | -3.92% |
| 2017 Q3 | 6.13 Billion INR | 6.53% |
| 2017 Q1 | 4.66 Billion INR | -13.81% |
| 2016 Q1 | 5.43 Billion INR | 10.47% |
| 2016 FY | 20.11 Billion INR | -4.15% |
| 2016 Q3 | 5.69 Billion INR | -8.65% |
| 2016 Q4 | 5.4 Billion INR | -4.99% |
| 2016 Q2 | 6.23 Billion INR | 14.74% |
| 2015 Q3 | 7.09 Billion INR | -8.71% |
| 2015 Q1 | 3.68 Billion INR | 48.05% |
| 2015 Q4 | 4.91 Billion INR | -30.69% |
| 2015 FY | 20.98 Billion INR | 67.64% |
| 2015 Q2 | 7.77 Billion INR | 110.92% |
| 2014 Q4 | 2.48 Billion INR | -26.08% |
| 2014 Q3 | 3.36 Billion INR | -5.6% |
| 2014 Q2 | 3.56 Billion INR | 13.14% |
| 2014 Q1 | 3.15 Billion INR | 54.23% |
| 2014 FY | 12.51 Billion INR | 17.98% |
| 2013 Q2 | 2.94 Billion INR | 16.16% |
| 2013 Q1 | 2.53 Billion INR | 70.32% |
| 2013 Q3 | 3.08 Billion INR | 4.96% |
| 2013 FY | 10.6 Billion INR | 36.53% |
| 2013 Q4 | 2.04 Billion INR | -33.85% |
| 2012 FY | 7.77 Billion INR | 13.43% |
| 2012 Q3 | 2.21 Billion INR | 2.37% |
| 2012 Q4 | 1.48 Billion INR | -32.75% |
| 2012 Q1 | 1.9 Billion INR | 0.0% |
| 2012 Q2 | 2.16 Billion INR | 13.41% |
| 2011 FY | 6.85 Billion INR | 12.01% |
| 2010 FY | 6.11 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aurobindo Pharma Limited | 154.68 Billion INR | 82.687% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | -115.4% |
| Granules India Limited | 16.79 Billion INR | -59.416% |
| Indoco Remedies Limited | 6.04 Billion INR | -343.292% |
| Achyut Healthcare Limited | 4.86 Million INR | -550829.85% |
| Ajanta Pharma Limited | 21.06 Billion INR | -27.14% |
| Alkem Laboratories Limited | 52.29 Billion INR | 48.791% |
| Alpa Laboratories Limited | 188.89 Million INR | -14077.559% |
| Brooks Laboratories Limited | 65.62 Million INR | -40711.795% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -330.371% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -1719.581% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -624.697% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 83.631% |
| Eris Lifesciences Limited | 10.42 Billion INR | -156.845% |
| FDC Limited | 8.33 Billion INR | -221.314% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 61.378% |
| Gufic Biosciences Limited | 4.16 Billion INR | -542.577% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -332.34% |
| Ipca Laboratories Limited | 29.8 Billion INR | 10.162% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -4003.756% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -13795.666% |
| Lasa Supergenerics Limited | 121.02 Million INR | -22027.324% |
| Laurus Labs Limited | 24.62 Billion INR | -8.776% |
| Lupin Limited | 123.71 Billion INR | 78.353% |
| Mankind Pharma Limited | 44.52 Billion INR | 39.847% |
| Medicamen Biotech Limited | 495.49 Million INR | -5304.838% |
| Medico Remedies Limited | 262.14 Million INR | -10116.026% |
| Megasoft Limited | 342.07 Million INR | -7728.989% |
| NATCO Pharma Limited | 25.73 Billion INR | -4.059% |
| Piramal Pharma Limited | 24.47 Billion INR | -9.439% |
| RPG Life Sciences Limited | 2.48 Billion INR | -978.562% |
| Sigachi Industries Limited | 2 Billion INR | -1237.508% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 89.639% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -549.501% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -2741.758% |
| Unichem Laboratories Limited | 4.86 Billion INR | -450.485% |
| Wanbury Limited | 1.73 Billion INR | -1447.442% |
| Windlas Biotech Limited | 1.33 Billion INR | -1900.351% |
| ZIM Laboratories Limited | 1.26 Billion INR | -2013.898% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 78.612% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 4545.623% |
| Divi's Laboratories Limited | 32.44 Billion INR | 17.445% |
| Hester Biosciences Limited | 1.27 Billion INR | -2002.673% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -363.222% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -1620.536% |
| Bal Pharma Limited | 770.19 Million INR | -3377.132% |
| Strides Pharma Science Limited | 14.38 Billion INR | -86.131% |
| Venus Remedies Limited | 2.18 Billion INR | -1127.018% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -359.254% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -801.082% |
| Shilpa Medicare Limited | 3.54 Billion INR | -655.054% |
| Aarti Drugs Limited | 8.31 Billion INR | -222.03% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -484.629% |
| Suven Life Sciences Limited | -200.79 Million INR | 13437.201% |
| Ind-Swift Limited | 2.17 Billion INR | -1132.696% |
| Valiant Laboratories Limited | -60.66 Million INR | 44245.951% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | -17.977% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -3009.696% |
| Themis Medicare Limited | 1.5 Billion INR | -1680.745% |
| Hikal Limited | 3.14 Billion INR | -752.053% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 42.724% |
| Sequent Scientific Limited | 2.97 Billion INR | -799.064% |
| Novartis India Limited | 1.32 Billion INR | -1918.291% |
| Wockhardt Limited | 16.24 Billion INR | -64.906% |
| Jubilant Pharmova Limited | 19.64 Billion INR | -36.337% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -183584.849% |
| Neuland Laboratories Limited | 8.24 Billion INR | -224.7% |
| Morepen Laboratories Limited | 6.16 Billion INR | -334.661% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -4216.147% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -3706.212% |